Guillain–Barré Syndrome Fact Sheet | National Institute of Neurological Disorders and Stroke. Available from: https://www.ninds.nih.gov/guillain-barre-syndrome-fact-sheet.
van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–82.
Dimachkie MM, Barohn RJ. Guillain–Barré syndrome and variants. Neurol Clin. 2013;31(2):491–510.
Article PubMed PubMed Central Google Scholar
Nakano Y, Kanda T. Pathology of Guillain–Barré syndrome. Clin Exp Neuroimmun. 2016;7(4):312–9. https://doi.org/10.1111/cen3.12342.
Willison HJ, Jacobs BC, van Doorn PA. Guillain–Barré syndrome. The Lancet. 2016;388(10045):717–27.
Guillain–Barré Syndrome | Campylobacter | CDC. 2022 [cited 2022 Nov 15]. Available from: https://www.cdc.gov/campylobacter/guillain-barre.html.
Mamishi S, Ashrafi MR, Mohammadi M, Zamani G, Pourakbari B, Mahmoudi S, et al. Cytomegalovirus infection and Guillain–Barré syndrome: the first case-control study in Iran. Iran J Child Neurol. 2021;15(4):35–41.
PubMed PubMed Central Google Scholar
Wallace LA, English SW, Fugate JE, Tosh PK. Acute Epstein-Barr virus infection presenting as Guillain-Barre syndrome. IDCases. 2021;1(25): e01196.
Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, Roodbol J, Hoogenboezem T, Jacobs E, et al. Mycoplasma pneumoniae triggering the Guillain–Barré syndrome: a case-control study. Ann Neurol. 2016;80(4):566–80.
Mori M, Kuwabara S, Miyake M, Noda M, Kuroki H, Kanno H, et al. Haemophilus influenzae infection and Guillain–Barré syndrome. Brain J Neurol. 2000;123(Pt 10):2171–8.
Jacobs BC, Rothbarth PH, van der Meché FGA, Herbrink P, Schmitz PIM, de Klerk MA, et al. The spectrum of antecedent infections in Guillain–Barré syndrome: a case-control study. Neurology. 1998;51(4):1110–5.
Article CAS PubMed Google Scholar
Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain–Barré syndrome. Drug Saf. 2009;32(4):309–23.
Article CAS PubMed Google Scholar
Guillain–Barré syndrome triggered by surgery in a Chinese population: a multicenter retrospective study. BMC Neurol. https://doi.org/10.1186/s12883-021-02067-1.
Huang C, Zhang Y, Deng S, Ren Y, Lu W. Trauma-related Guillain–Barré syndrome: systematic review of an emerging concept. Front Neurol. 2020;6(11): 588290.
Fischer GH, Paterek E. Campylobacter. StatPearls [Internet]. StatPearls Publishing; 2022 [cited 2022 Nov 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537033/.
Rhodes KM, Tattersfield AE. Guillain–Barre syndrome associated with Campylobacter infection. Br Med J Clin Res Ed. 1982;285(6336):173–4.
Article CAS PubMed PubMed Central Google Scholar
Svedhem A, Kaijser B. Campylobacter fetus subspecies jejuni: a common cause of diarrhea in Sweden. J Infect Dis. 1980;142(3):353–9.
Article CAS PubMed Google Scholar
Nyati KK, Nyati R. Role of Campylobacter jejuni infection in the pathogenesis of Guillain–Barré Syndrome: an update. BioMed Res Int. 2013;13(2013): e852195.
Comparative study of preceding Campylobacter jejuni infection in Guillain–Barré syndrome in Japan and The Netherlands. J Neurol Neurosurg Psychiatry. Available from: https://jnnp.bmj.com/content/70/5/693
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain–Barré syndrome. Ann Neurol. 1990;27(Suppl):S21-24.
Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet Lond Engl. 1978;2(8093):750–3.
Albers JW, Kelly JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve. 1989;12(6):435.
Article CAS PubMed Google Scholar
Leonhard SE, van der Eijk AA, Andersen H, Antonini G, Arends S, Attarian S, et al. An international perspective on preceding infections in Guillain–Barré syndrome: the IGOS-1000 cohort. Neurology. 2022;99(12):e1299–313.
Schmidt-Ott R, Schmidt H, Feldmann S, Brass F, Krone B, Gross U. Improved serological diagnosis stresses the major role of Campylobacter jejuni in Triggering Guillain–Barré syndrome. Clin Vaccine Immunol. 2006;13(7):779–83.
Article CAS PubMed PubMed Central Google Scholar
Schiaffino F, Kosek MN. Intestinal and extra-intestinal manifestations of campylobacter in the immunocompromised host. Curr Treat Options Infect Dis. 2020;12(4):361–74.
Zautner AE, Johann C, Strubel A, et al. Seroprevalence of campylobacteriosis and relevant post-infectious sequelae. Eur J Clin Microbiol Infect Dis. 2014;33:1019–27. https://doi.org/10.1007/s10096-013-2040-4.
Article CAS PubMed PubMed Central Google Scholar
Allos BM. Association between Campylobacter infection and Guillain–Barré syndrome. J Infect Dis. 1997;176(Suppl 2):S125-128.
Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, et al. A bacterium lipopolysaccharide that elicits Guillain–Barré syndrome has a GM1 ganglioside-like structure. J Exp Med. 1993;178(5):1771–5.
Article CAS PubMed Google Scholar
Kuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, et al. Campylobacter jejuni strains from patients with Guillain–Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann Neurol. 1993;33(3):243–7.
Article CAS PubMed Google Scholar
Gruenewald R, Ropper AH, Lior H, Chan J, Lee R, Molinaro VS. Serologic evidence of Campylobacter jejuni/coli enteritis in patients with Guillain–Barré syndrome. Arch Neurol. 1991;48(10):1080–2.
Article CAS PubMed Google Scholar
Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain–Barré syndrome in northern China Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118(3):597–605.
Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. Regional variation of Guillain–Barré syndrome. Brain. 2018;141(10):2866–77.
Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain–Barré syndrome. N Engl J Med. 1995;333(21):1374–9.
Article CAS PubMed Google Scholar
Sharma A, Lal V, Modi M, Vaishnavi C, Prabhakar S. Campylobacter jejuni infection in Guillain–Barré syndrome: a prospective case control study in a tertiary care hospital. Neurol India. 2011;59(5):717.
Comments (0)